gip/glp 1-agonist tirzepatide Main physiological actions of the dual GIP and GLP-1 agonist Tirzepatide's Unique Mechanism of Action
Description
95% CI, 0.27 to 0.92)
Data on the CV benefits of GLP-1 RAs and their use in clinical practice were summarized
H., Aby, E
(Supplementary Clinical Sequelae 1)
The new label for Ozempic is based on the results of the FLOW trial, which showed a statistically significant reduction in kidney disease progression, as well as cardiovascular and kidney death with a 1 mg/kg weekly dose of the injectable drug compared to placebo
Tirzepatide sublingual drops Tirzepatide drops represent the dual-agonist approach, targeting both GLP-1 and GIP receptors simultaneously
